Roxadustat: First Global Approval

Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018

(2018) Steven Fishbane et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects

(2018) Dorien Groenendaal-van de Meent et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects

(2018) T. Shibata et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism

(2017) Volker H. Haase   Hemodialysis International

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China

(2017) Nan Chen et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

(2016) Robert Provenzano et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

(2016) R. Provenzano et al.   Clinical Journal of the American Society of Nephrology

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients

(2015) A. Besarab et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

(2015) Anatole Besarab et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION